Sentences with phrase «targeted lung cancer treatment»

Not exact matches

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

In the group that received targeted treatment for ALK - positive lung cancer, each category of tumor reduction was associated with corresponding gains in PFS and OS.

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

«Ultimately, figuring out how to target PC may help researchers develop new, more effective therapeutic strategies to improve upon current lung cancer treatments, which are limited and harmful.»

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

The treatment is promising enough that research teams around the world are developing similar stem cell therapies that can target and eradicate cancers of the prostate, lung, breast, skin and other tissues.

«Antibody - targeted treatment developed for recurrent small - cell lung cancer.»

The FDA granted approval to durvalumab (IMFINZI ®, AstraZeneca), a checkpoint immunotherapy that targets the PD - 1 / PD - L1 pathway, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn't progressed after prior chemo - radiation treatment.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Therefore the concept of administering treatment directly to the target tissue has been pursued in lung cancer with many forms such as; intratumoral6, 7, aerosol8 - 10 and intracavitary11.

Lung cancer treatment is an evolving field of science, currently there are several pathways under investigation as a possible treatment target.1 - 3 Targeted treatment is currently considered to be more efficient compared to the non-specific cytotoxic drugs, however; the small number of patients identified with mutations, limit the application of these drugs.

Cancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develoCancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor development.

City of Hope patients have access to a wide variety of clinical trials looking into early - detection for lung cancer, the newest chemotherapy treatments, targeted therapies and surgical and radiation approaches — all with the goal of helping extend life.

Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?

Despite these successes two major problems remain: first, the majority of lung cancer patients have tumours without mutations in targetable genes and; second, all patients eventually develop resistance to treatment with these targeted agents.

Inform and educate clinicians as to updates and revisions of their Molecular testing Guideline for the Selection of Lung cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Linase Inhibitors 2018

As I shared, we know that 15 of these genes can currently be targets for improved lung cancer treatments.

Indeed, it says its technology will allow doctors to access early - stage lung cancer without incisions, allowing for more accurate diagnosis, as well as more targeted treatment.